Zacks Rating on CEPHEID (CPHD)

CEPHEID (CPHD) : The consensus on CEPHEID (CPHD) based on 14 analyst recommendation on the company stock is 2.07, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 6 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 7 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

CEPHEID (CPHD) : The highest short term price target forecast on CEPHEID (CPHD) is $47 and the lowest target price is $30. A total of 11 equity analysts are currently covering the company. The average price of all the analysts is $39.09 with a standard deviation of $5.22.


Shares of Cepheid rose by 1.36% in the last five trading days and 12.87% for the last 4 weeks. Cepheid is up 31.4% in the last 3-month period. Year-to-Date the stock performance stands at -0.11%. CEPHEID (NASDAQ:CPHD): stock turned positive on Tuesday. Though the stock opened at $35.97, the bulls momentum made the stock top out at $36.66 level for the day. The stock recorded a low of $35.93 and closed the trading day at $36.49, in the green by 1.87%. The total traded volume for the day was 385,277. The stock had closed at $35.82 in the previous days trading.

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps, including sample preparation, DNA amplification and detection. The Companys systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to DNA amplification and detection, serves reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.